The FDA stepped up warnings on antibiotics like Johnson & Johnson’s Levaquin, adding long-term risks to the drugs’ current black box. The drugs'…

GlaxoSmithKline CEO Andrew Witty is sitting pretty. For the second straight quarter, his much-maligned growth strategy has come through for the drugmaker,…

Bayer’s pharma lineup churned out growth for yet another quarter, racking up a 5.5% sales hike to €4.1 billion as the blood thinner Xarelto and vision med…

GlaxoSmithKline is not planning to exit the U.K. just because the U.K. is exiting the European Union. As if to emphasize its commitment, the drugmaker today…

The Philadelphia host committee of the Democratic National Convention has hired a healthcare agency to manage its social media and digital this week--and …

So far, the group of newly approved multiple myeloma meds hasn’t proved much of a threat to older, more established therapies. But that could all change soon.

Rebel Depomed investor Starboard Value wants a special meeting as soon as possible--and to get its wish, it’s taking matters into its own hands.

In its second Opdivo tie-up in as many days, Bristol-Myers Squibb has teamed up with Johnson & Johnson to test its drug in yet another variety of lung…

Looking for a bright spot in the gloom of Gilead Sciences’ second-quarter numbers? Look no further than its HIV franchise, where the latest generation of meds…